Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K)

10/07/2021 | 08:20am EST

Item 8.01 Other Events.

On October 7, 2021, Ultragenyx Pharmaceutical Inc. (the "Company") and GeneTx Biotherapeutics LLC ("GeneTx") issued a press release (the "Press Release") announcing that the first patient has been dosed in the Phase 1/2 study of GTX-102, an investigational treatment for Angelman syndrome, with three other patients enrolled and scheduled to begin dosing. A copy of the Press Release is filed as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated October 7, 2021.
104         The cover page from the Company's Current Report on Form 8-K dated
            October 7, 2021 formatted in Inline XBRL.





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ULTRAGENYX PHARMACEUTICAL INC.
12/02Genetx and ultragenyx announce presentations at upcoming 2021 fast global summit & gala
AQ
12/01GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala
GL
12/01Ultragenyx Commences Dosing in Phase 1/2 Study of UX053 in Glycogen Storage Disease Typ..
MT
12/01Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA ..
AQ
12/01Ultragenyx Pharmaceutical Inc. Announces First Patient Dosed in Phase 1/2 Clinical Stud..
CI
11/29Ultragenyx to Present at Evercore 4th Annual HealthconX Conference
GL
11/29Ultragenyx to Present at Evercore 4th Annual HealthconX Conference
GL
11/29Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV ..
AQ
11/29Ultragenyx Pharmaceutical Inc. Announces New Long-Term Durability Data from Phase 1/2 S..
CI
11/03ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations